Phase
Condition
Cardiac Disease
Cardiovascular Disease
Heart Disease
Treatment
18F-FDG
Clinical Study ID
Ages > 30 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age criteria as follows:
Native valve endocarditis >30 years
Prosthetic valve endocarditis/device infection >50 years
Non-infective post-operative patients >65 years
Additional inclusion criteria:
Completion of informed consent
Established diagnosis of one of the conditions listed below:
I. Native valve infective endocarditis; established diagnosis by Dukes criteria II. Prosthetic valve or device-related infection; established diagnosis by Dukes criteria (in the case of valves), or by microbiological, haematological and biochemical grounds (in the case of device-related infection) III. Recent implant of prosthetic valve and/or cardiac device
Exclusion
Exclusion Criteria:
Inability or unwilling to give informed consent
Women who are pregnant, breastfeeding or of child-bearing potential (women who haveexperienced menarche, are pre-menopausal and have not been sterilised) will not beenrolled into the trial
Major intercurrent illness with life-expectancy <2 years
Renal dysfunction (eGFR less than or equal to 30ml/min/1.73m2)
Adverse reaction or hypersensitivity to 18F-FDG PET tracer
NYHA Class IV heart failure
Insulin-dependent diabetes mellitus
Patients with atrial fibrillation and poor rate control
Contraindications to MR for patients in the groups undergoing PET/MR including anypatient with suspected metal in their eyes
Previous history of contrast allergy of adverse reactions (iodinated contrast inpatients undergoing PET/CT and gadolinium in patients undergoing PET/MR)
Study Design
Connect with a study center
Queen's Medical Research Institute
Edinburgh, Midlothian EH16 4TJ
United KingdomSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.